TL;DR
This paper discusses the principal stratum strategy in drug development, emphasizing its potential to improve causal inference in the presence of intercurrent events, and advocates for its integration with the ICH E9(R1) estimand framework.
Contribution
It introduces the principal stratum strategy as a method to address intercurrent events, illustrating its application and discussing assumptions and sensitivity analyses in drug development.
Findings
Principal stratum strategy clarifies causal effects post-intercurrent events.
Integration with ICH E9(R1) enhances transparency and appropriateness of analyses.
Most assumptions are unverifiable and require scientific justification.
Abstract
A randomized trial allows estimation of the causal effect of an intervention compared to a control in the overall population and in subpopulations defined by baseline characteristics. Often, however, clinical questions also arise regarding the treatment effect in subpopulations of patients, which would experience clinical or disease related events post-randomization. Events that occur after treatment initiation and potentially affect the interpretation or the existence of the measurements are called {\it intercurrent events} in the ICH E9(R1) guideline. If the intercurrent event is a consequence of treatment, randomization alone is no longer sufficient to meaningfully estimate the treatment effect. Analyses comparing the subgroups of patients without the intercurrent events for intervention and control will not estimate a causal effect. This is well known, but post-hoc analyses of this…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Code & Models
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
